Antony Cooper is the research director of the Australian Parkinson’s Mission (APM) and head of the Neurodegeneration & Neurogenomics Laboratory at the Garvan Institute of Medical Research (Australia). He completed his Bachelor’s degree with honours at the University of Otago (New Zealand) prior to a PhD at McGill University. After post-doctoral studies at the University of Oregon’s Institute of Molecular Biology, he gained tenure at the University of Missouri (1996) and then moved to the Garvan Institute (2006). His lab studies the molecular mechanisms of Parkinson’s Disease (PD). Since 2019, he has focused on the aims of the APM, which include accelerating the identification of disease-modifying PD treatments using a framework based on the integration of clinical trials with genomic stratification approaches, biomarker assay development and deployment and the application of relevant human cell models.